vs
LXP Industrial Trust（LXP）与自然阳光（NATR）财务数据对比。点击上方公司名可切换其他公司
自然阳光的季度营收约是LXP Industrial Trust的1.4倍（$123.8M vs $86.7M），LXP Industrial Trust净利率更高（33.2% vs 3.3%，领先29.9%），自然阳光同比增速更快（4.7% vs -14.0%），过去两年自然阳光的营收复合增速更高（5.6% vs 0.3%）
LXP工业信托是一家公开上市的房地产投资信托，专注于持有、运营和投资美国核心市场的优质工业地产，主要涵盖配送中心、物流设施及轻型工业物业，服务电商、第三方物流、先进制造等领域租户，为投资者创造长期稳定收益。
自然阳光产品公司（简称NSP）主营膳食补充剂与个人护理产品的生产制造，产品涵盖草本补充剂、维生素、矿物质制剂等品类。公司总部设于犹他州利希，生产工厂位于犹他州西班牙福克，是该领域知名的健康产品生产商。
LXP vs NATR — 直观对比
营收规模更大
NATR
是对方的1.4倍
$86.7M
营收增速更快
NATR
高出18.7%
-14.0%
净利率更高
LXP
高出29.9%
3.3%
两年增速更快
NATR
近两年复合增速
0.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $86.7M | $123.8M |
| 净利润 | $28.8M | $4.1M |
| 毛利率 | 81.5% | 72.5% |
| 营业利润率 | 34.6% | 4.3% |
| 净利率 | 33.2% | 3.3% |
| 营收同比 | -14.0% | 4.7% |
| 净利润同比 | — | 1379.4% |
| 每股收益（稀释后） | — | $0.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LXPNATR
| Q4 25 | $86.7M | $123.8M | ||
| Q3 25 | $86.9M | $128.3M | ||
| Q2 25 | $87.7M | $114.8M | ||
| Q1 25 | $88.9M | $113.2M | ||
| Q4 24 | $100.9M | $118.2M | ||
| Q3 24 | $85.6M | $114.6M | ||
| Q2 24 | $85.8M | $110.6M | ||
| Q1 24 | $86.3M | $111.0M |
净利润LXPNATR
| Q4 25 | $28.8M | $4.1M | ||
| Q3 25 | $36.3M | $5.3M | ||
| Q2 25 | $29.1M | $5.3M | ||
| Q1 25 | $19.0M | $4.7M | ||
| Q4 24 | — | $-321.0K | ||
| Q3 24 | $6.3M | $4.3M | ||
| Q2 24 | $5.4M | $1.3M | ||
| Q1 24 | $-269.0K | $2.3M |
毛利率LXPNATR
| Q4 25 | 81.5% | 72.5% | ||
| Q3 25 | 82.3% | 73.3% | ||
| Q2 25 | 81.9% | 71.7% | ||
| Q1 25 | 80.7% | 72.1% | ||
| Q4 24 | 85.3% | 72.0% | ||
| Q3 24 | 82.5% | 71.3% | ||
| Q2 24 | 82.0% | 71.4% | ||
| Q1 24 | 82.4% | 71.2% |
营业利润率LXPNATR
| Q4 25 | 34.6% | 4.3% | ||
| Q3 25 | 50.4% | 7.0% | ||
| Q2 25 | 33.7% | 3.7% | ||
| Q1 25 | 21.8% | 5.4% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | 7.9% | 4.6% | ||
| Q2 24 | 6.9% | 5.1% | ||
| Q1 24 | 1.0% | 4.2% |
净利率LXPNATR
| Q4 25 | 33.2% | 3.3% | ||
| Q3 25 | 41.7% | 4.2% | ||
| Q2 25 | 33.2% | 4.6% | ||
| Q1 25 | 21.4% | 4.2% | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | 7.4% | 3.8% | ||
| Q2 24 | 6.3% | 1.2% | ||
| Q1 24 | -0.3% | 2.1% |
每股收益（稀释后）LXPNATR
| Q4 25 | — | $0.23 | ||
| Q3 25 | $0.12 | $0.30 | ||
| Q2 25 | $0.09 | $0.28 | ||
| Q1 25 | $0.06 | $0.25 | ||
| Q4 24 | — | $-0.02 | ||
| Q3 24 | $0.02 | $0.23 | ||
| Q2 24 | $0.01 | $0.07 | ||
| Q1 24 | $-0.01 | $0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $170.4M | $93.9M |
| 总债务越低越好 | $1.4B | — |
| 股东权益账面价值 | $2.0B | $161.6M |
| 总资产 | $3.5B | $261.1M |
| 负债/权益比越低杠杆越低 | 0.66× | — |
8季度趋势，按日历期对齐
现金及短期投资LXPNATR
| Q4 25 | $170.4M | $93.9M | ||
| Q3 25 | $229.7M | $95.6M | ||
| Q2 25 | $71.0M | $81.3M | ||
| Q1 25 | $70.9M | $86.5M | ||
| Q4 24 | $101.8M | $84.7M | ||
| Q3 24 | $55.0M | $78.7M | ||
| Q2 24 | $48.7M | $68.7M | ||
| Q1 24 | $293.8M | $77.8M |
总债务LXPNATR
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $2.1M |
股东权益LXPNATR
| Q4 25 | $2.0B | $161.6M | ||
| Q3 25 | $2.1B | $166.7M | ||
| Q2 25 | $2.1B | $163.7M | ||
| Q1 25 | $2.1B | $167.1M | ||
| Q4 24 | $2.1B | $161.0M | ||
| Q3 24 | $2.1B | $162.6M | ||
| Q2 24 | $2.1B | $156.4M | ||
| Q1 24 | $2.2B | $159.7M |
总资产LXPNATR
| Q4 25 | $3.5B | $261.1M | ||
| Q3 25 | $3.7B | $264.8M | ||
| Q2 25 | $3.7B | $254.9M | ||
| Q1 25 | $3.8B | $252.7M | ||
| Q4 24 | $3.8B | $240.9M | ||
| Q3 24 | $3.9B | $245.3M | ||
| Q2 24 | $3.9B | $235.8M | ||
| Q1 24 | $4.2B | $247.3M |
负债/权益比LXPNATR
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.01× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $188.7M | $9.9M |
| 自由现金流经营现金流 - 资本支出 | — | $7.6M |
| 自由现金流率自由现金流/营收 | — | 6.1% |
| 资本支出强度资本支出/营收 | — | 1.9% |
| 现金转化率经营现金流/净利润 | 6.56× | 2.41× |
| 过去12个月自由现金流最近4个季度 | — | $28.8M |
8季度趋势，按日历期对齐
经营现金流LXPNATR
| Q4 25 | $188.7M | $9.9M | ||
| Q3 25 | $63.5M | $18.5M | ||
| Q2 25 | $44.3M | $4.3M | ||
| Q1 25 | $39.0M | $2.6M | ||
| Q4 24 | $211.2M | $12.2M | ||
| Q3 24 | $64.6M | $9.6M | ||
| Q2 24 | $38.5M | $1.3M | ||
| Q1 24 | $38.9M | $2.2M |
自由现金流LXPNATR
| Q4 25 | — | $7.6M | ||
| Q3 25 | — | $16.8M | ||
| Q2 25 | — | $3.0M | ||
| Q1 25 | — | $1.5M | ||
| Q4 24 | — | $10.0M | ||
| Q3 24 | — | $7.9M | ||
| Q2 24 | — | $-2.0M | ||
| Q1 24 | — | $-1.5M |
自由现金流率LXPNATR
| Q4 25 | — | 6.1% | ||
| Q3 25 | — | 13.1% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 8.5% | ||
| Q3 24 | — | 6.9% | ||
| Q2 24 | — | -1.9% | ||
| Q1 24 | — | -1.4% |
资本支出强度LXPNATR
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | 3.0% | ||
| Q1 24 | — | 3.3% |
现金转化率LXPNATR
| Q4 25 | 6.56× | 2.41× | ||
| Q3 25 | 1.75× | 3.46× | ||
| Q2 25 | 1.52× | 0.81× | ||
| Q1 25 | 2.05× | 0.55× | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.18× | 2.21× | ||
| Q2 24 | 7.09× | 0.97× | ||
| Q1 24 | — | 0.94× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LXP
暂无分部数据
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
